advertisement
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (25)
Showing records 1 to 25
Search within classification 11.16 Vehicles, delivery systems, pharmacokinetics, formulation55601 Improvement in glaucoma patient quality of life by therapy switch to preservative-free timolol/dorzolamide fixed combination
Abegão Pinto L; Vandewalle E; Gerlier L; Stalmans I;
Ophthalmologica 2014; 231: 166-171
55673 Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog
Niwano Y; Iwasawa A; Ayaki M
Ophthalmology and eye diseases 2014; 6: 5-12
55709 The effectiveness of endonasal electrophoresis of neuroprotective agents used in the rehabilitative treatment of the patients presenting with primary open angle glaucoma
Nazarova GA; Konchugova TV; Iurova OV; Sichinava NV; Turova EA; Rassulova MA; Morozova NE
Voprosy kurortologii, fizioterapii, i lechebnoĭ fizicheskoĭ kultury 2013; 0: 27-30
55376 Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients With Existing Superficial Punctate Keratitis
Suzuki K; Teranishi S; Sagara T; Yoshino H; Nakayama M; Enoki M; Nuno Y; Hirano S; Wakuta M; Takahashi N; Tokuhisa K; Kondo Y; Shiraishi R; Ishida Y; Sonoda KH;
Journal of Glaucoma 2015; 24: e145-e150
55170 In vivo performance of a drug-eluting contact lens to treat glaucoma for a month
Ciolino JB; Stefanescu CF; Ross AE; Salvador-Culla B; Cortez P; Ford EM; Wymbs KA; Sprague SL; Mascoop DR; Rudina SS; Trauger SA; Cade F; Kohane DS
Biomaterials 2014; 35: 432-439
55090 Development of inclusion complex of brinzolamide with hydroxypropyl-β-cyclodextrin
Zhang Y; Ren K; He Z; Li H; Chen T; Lei Y; Xia S; He G; Xie Y; Zheng Y; Song X
Carbohydrate polymers 2013; 98: 638-643
55298 Biodegradable in situ gelling delivery systems containing pilocarpine as new antiglaucoma formulations: effect of a mercaptoacetic acid/N-isopropylacrylamide molar ratio
Lai JY
Drug design, development and therapy 2013; 7: 1273-1285
55757 Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation
Franca JR; Foureaux G; Fuscaldi LL; Ribeiro TG; Rodrigues LB; Bravo R; Castilho RO; Yoshida MI; Cardoso VN; Fernandes SO; Cronemberger S; Ferreira AJ; Faraco AA
PLoS ONE 2014; 9: e95461
55148 Molecular dynamic simulations of ocular tablet dissolution
Ru Q; Fadda HM; Li C; Paul D; Khaw PT; Brocchini S; Zloh M
Journal of Chemical Information and Modeling 2013; 53: 3000-3008
55748 Formulation and In-vitro Characterization of Sustained Release Matrix Type Ocular Timolol Maleate Mini-Tablet
Mortazavi SA; Jafariazar Z; Ghadjahani Y; Mahmoodi H; Mehtarpour F
Iranian journal of pharmaceutical research : IJPR 2014; 13: 19-27
55443 Acetazolamide encapsulated dendritic nano-architectures for effective glaucoma management in rabbits
Mishra V; Jain NK
International Journal of Pharmaceutics 2014; 461: 380-390
55203 Glaucoma and dry eye. Current concepts and future perspectives
Steven P; Cursiefen C
Ophthalmologe 2013; 110: 1155-1159
55440 Probing influence of methodological variation on active loading of acetazolamide into nanoliposomes: biophysical, in vitro, ex vivo, in vivo and rheological investigation
Pisal PB; Joshi MA; Padamwar MN; Patil SS; Pokharkar VB
International Journal of Pharmaceutics 2014; 461: 82-88
55211 Chick chorioallantoic membrane model for in ovo evaluation of timolol maleate-brimonidine tartrate ocular inserts
Ravindran VK; Repala S; Subadhra S; Appapurapu AK
Drug Delivery 2014; 21: 307-314
55672 Changes in the morphological and functional patterns of the ocular surface in patients treated with prostaglandin analogues after the use of TSP 0.5%® preservative-free eyedrops: a prospective, multicenter study
Iester M; Oddone F; Fogagnolo P; Frezzotti P; Figus M;
Ophthalmic Research 2014; 51: 146-152
55342 How ocular surface disease impacts the glaucoma treatment outcome
Kaštelan S; Tomić M; Metež Soldo K; Salopek-Rabatić J
BioMed research international 2013; 2013: 696328
55232 Meta analysis about the efficacy and safety of anti-ocular hypertension eye drops without benzalkonium chloride
Wang YQ; Wang X; Liu P
Asian Pacific journal of tropical medicine 2013; 6: 1004-1008
55321 Benzalkonium chloride and glaucoma
Rasmussen CA; Kaufman PL; Kiland JA
Journal of Ocular Pharmacology and Therapeutics 2014; 30: 163-169
55729 Potential use of niosomal hydrogel as an ocular delivery system for atenolol
Abu Hashim II; El-Dahan MS; Yusif RM; Abd-Elgawad AE; Arima H
Biological & Pharmaceutical Bulletin 2014; 37: 541-551
55467 In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells
Kim EJ; Kim YH; Kang SH; Lee KW; Park YJ
Korean Journal of Ophthalmology 2013; 27: 446-453
55642 In situ gelling dorzolamide loaded chitosan nanoparticles for the treatment of glaucoma
Katiyar S; Pandit J; Mondal RS; Mishra AK; Chuttani K; Aqil M; Ali A; Sultana Y
Carbohydrate polymers 2014; 102: 117-124
55339 Development of dorzolamide loaded 6-o-carboxymethyl chitosan nanoparticles for open angle glaucoma
Shinde U; Ahmed MH; Singh K
Journal of Drug Delivery 2013; 2013: 562727
55316 Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops
Rosin LM; Bell NP
Clinical Ophthalmology 2013; 7: 2131-2135
55495 Development and characterization of nano-fiber patch for the treatment of glaucoma
Gagandeep ; Garg T; Malik B; Rath G; Goyal AK
European Journal of Pharmaceutical Sciences 2014; 53: 10-16
55384 Nanotechnology and glaucoma: a review of the potential implications of glaucoma nanomedicine
Kim NJ; Harris A; Gerber A; Tobe LA; Amireskandari A; Huck A; Siesky B
British Journal of Ophthalmology 2014; 98: 427-431
